Corium International — Technical Presentation (February 2016)
12 slides from Corium International's technical presentation, Feb 22, 2016
Slide 1: Forward-looking Statements
Forward-looking Statements This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding our business strategy, clinical trial timing and plans, the achieveme
Slide 2: Phase 1 Study Overview
Phase 1 Study Overview Open label, partial crossover study Three treatments Memantine TDS, single-dose, once-weekly patch* targeted to deliver 28 mg/day Memantine TDS, single-dose, 3-day patch* targeted to deliver 28 mg/day Seven consecutive days of once-daily oral Namenda XR 28 mg capsule as compar
Slide 3: Phase 1 Study Overview (cont.)
Phase 1 Study Overview (cont.) Follow-on clinical wear study Evaluate effect of modified patch application procedure and configuration Skin tolerability Adhesion
Slide 4: 7-Day Delivery Demonstrated
7-Day Delivery Demonstrated* Oral Namenda XR: administered once daily for 7 days; plasma sampling during Day 1 and on Days 7 through 15 Memantine TDS: single application of once-weekly TDS; plasma sampling during patch application (Days 1-7) and post patch removal (Days 8-15) Memantine TDS: single a
Slide 5: Sustained and Controlled Delivery Demonstrated
Sustained and Controlled Delivery Demonstrated Sustained PK profile on Day 7 Controlled delivery with minimal peak to trough fluctuation Namenda XR: administered once daily for 7 days; plasma sampling on Day 7 (0-24 hours) Memantine TDS: single application of once-weekly patch with plasma sampling o
Slide 6: 3-Day TDS: Similar PK to Oral Projected at Steady State
3-Day TDS: Similar PK to Oral Projected at Steady State *TDS steady-state concentrations projected for Days 24-27 immediately after nine consecutive 3-day patch applications **28 mg oral projection based on observed data; 28 mg TDS projection based on observed data with patch size scaled for bioequi
Slide 7: 3-Day TDS: Potential Basis for Bioequivalence Approach
3-Day TDS: Potential Basis for Bioequivalence Approach Geometric Mean Ratio TDS:Oral for PK parameters were between 95%-105% Intra-subject coefficient of variation was 60% Acceptance criteria for bioequivalence are 90% confidence intervals within 80%-125% limits 134 subjects in a two-way crossover s
Slide 8: Once-weekly TDS: Similar PK to Oral Projected at Steady State
Once-weekly TDS: Similar PK to Oral Projected at Steady State Sustained and controlled TDS delivery at steady state* Corplex Memantine area under the curve at steady state similar to oral** Optimization expected to result in bioequivalence *TDS steady-state concentrations projected for Week 4 immedi
Slide 9: Safety and Skin Tolerability
Safety and Skin Tolerability Local skin tolerability in PK portion of the study Moderate to high skin irritation for 3-day and once-weekly patch 4 subjects discontinued Systemic safety Similarly infrequent for both treatments No systemic adverse events unique to the transdermal delivery Follow-on we
Slide 10: Key Phase 1 Conclusions
Key Phase 1 Conclusions Sustained and controlled PK in target age group (50-80) Achievement of plasma concentrations comparable to Namenda XR 28 mg Patch size can be adjusted to deliver various doses equivalent to Namenda XR Acceptable safety and skin tolerability for 3-day TDS based on wear study O
Slide 11: Key Phase 1 Conclusions
Key Phase 1 Conclusions ee Sustained and controlled PK in target age group (50-80) Achievement of plasma concentrations comparable to Namenda XR 28 mg Patch size can be adjusted to deliver various doses equivalent to Namenda XR Acceptable safety and skin tolerability for 3-day TDS based on wear stud
Slide 12: Corium International, Inc.
Corium International, Inc. Nasdaq: CORI February 22, 2016 (©2018 Corum AN Rights Resend.
Corium International — Technical Presentation (February 2016) on 6ix